Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation

Chronic myelogenous leukaemia (CML) is a clonal malignancy of the pluripotent haematopoietic stem cell, characterised by an uncontrolled proliferation and expansion of myeloid progenitors expressing a fusion oncogene, BCR-ABL, the molecular counterpart of the Ph1 chromosome. The tyrosine kinase (TK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Deutsch, E, Maggiorella, L, Wen, B, Bonnet, M L, Khanfir, K, Frascogna, V, Turhan, A G, Bourhis, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409959/
https://www.ncbi.nlm.nih.gov/pubmed/15494718
http://dx.doi.org/10.1038/sj.bjc.6602190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409959/
https://www.ncbi.nlm.nih.gov/pubmed/15494718
http://dx.doi.org/10.1038/sj.bjc.6602190

Ejemplares similares